CDK4 inhibition diminishes p53 activation by MDM2 antagonists

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2041-4889

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: CDK4 inhibition diminishes p53 activation by MDM2 antagonists ; volume:9 ; number:9 ; day:11 ; month:9 ; year:2018 ; pages:1-16 ; date:9.2018
Cell death & disease ; 9, Heft 9 (11.9.2018), 1-16, 9.2018

Creator: Sriraman, Anusha

Contributor: Dickmanns, Antje
Najafova, Zeynab
Johnsen, Steven A.
Dobbelstein, Matthias
SpringerLink (Online service)

DOI: 10.1038/s41419-018-0968-0

URN: urn:nbn:de:101:1-2018102814500845316868

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:01 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Sriraman, Anusha
Dickmanns, Antje
Najafova, Zeynab
Johnsen, Steven A.
Dobbelstein, Matthias
SpringerLink (Online service)

Other Objects (12)

Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists

Hochschulschrift

NMR high resolution spectroscopy and X-ray crystallography for development of MDM2/X-p53 interaction antagonists

Evolution of the p53-MDM2 pathway

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

Hochschulschrift

Small-Molecule Inhibitors of p53-MDM2 interactions

Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype

Hochschulschrift

Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2

Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization

Hochschulschrift

Engineering a synthetic p53-Mdm2 network in budding yeast

Explaining oscillations and variability in the p53-Mdm2 system

Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists

Hochschulschrift

NMR high resolution spectroscopy and X-ray crystallography for development of MDM2/X-p53 interaction antagonists

Evolution of the p53-MDM2 pathway

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

Hochschulschrift

Small-Molecule Inhibitors of p53-MDM2 interactions

Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype

Hochschulschrift

Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2

Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization

Hochschulschrift

Engineering a synthetic p53-Mdm2 network in budding yeast

Explaining oscillations and variability in the p53-Mdm2 system

Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists

Hochschulschrift

NMR high resolution spectroscopy and X-ray crystallography for development of MDM2/X-p53 interaction antagonists

Evolution of the p53-MDM2 pathway

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

Hochschulschrift

Small-Molecule Inhibitors of p53-MDM2 interactions

Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype

Hochschulschrift

Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2

Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization

Hochschulschrift

Engineering a synthetic p53-Mdm2 network in budding yeast

Explaining oscillations and variability in the p53-Mdm2 system

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists

NMR high resolution spectroscopy and X-ray crystallography for development of MDM2/X-p53 interaction antagonists

Evolution of the p53-MDM2 pathway

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

Small-Molecule Inhibitors of p53-MDM2 interactions

Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype

Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2

Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization

Engineering a synthetic p53-Mdm2 network in budding yeast

Explaining oscillations and variability in the p53-Mdm2 system

Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists

NMR high resolution spectroscopy and X-ray crystallography for development of MDM2/X-p53 interaction antagonists

Evolution of the p53-MDM2 pathway

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

Small-Molecule Inhibitors of p53-MDM2 interactions

Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype

Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2

Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization

Engineering a synthetic p53-Mdm2 network in budding yeast

Explaining oscillations and variability in the p53-Mdm2 system

Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists

NMR high resolution spectroscopy and X-ray crystallography for development of MDM2/X-p53 interaction antagonists

Evolution of the p53-MDM2 pathway

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

Small-Molecule Inhibitors of p53-MDM2 interactions

Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype

Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2

Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization

Engineering a synthetic p53-Mdm2 network in budding yeast

Explaining oscillations and variability in the p53-Mdm2 system

Related objects

Reset password